Undertreatment of Depression and Comorbid Anxiety Translates Into Costly Mismanagement of Resources and Poor Patient Outcomes

According to the literature and measured against national standards for quality of care, treatment of depression is substandard. MCOs that frequently adopt step therapy to reduce pharmacy budgets might do well to re-examine those programs in light of the overall medical cost to the system and the quality of care that those patients receive. This publication explores ways in which providers, payers, and employer purchasers can contribute to an overall improvement in quality of care.


  • Why, and to what extent, depression and comorbid anxiety are underdiagnosed and undertreated in our society
  • How HEDIS tracks and documents substandard treatment
  • What major stakeholders can do to improve care and outcomes for patients with depression and comorbid anxiety
  • The clinical and economic importance of compliance with medication therapy
  • National trends in the pharmaceutical treatment of anxiety